Receptor News and Research

RSS

Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children

Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults

11 Sep 2026

Refined starch activates immune pathways after low-carb weight loss

After substantial weight loss on a very-low-carbohydrate diet, participants who switched to a diet rich in refined starch showed greater activation of circulating immune and metabolic pathways than those who continued the low-carbohydrate diet or consumed a high-carbohydrate diet rich in added sugar. Mouse experiments suggested that activation of the complement immune pathway may help explain the inflammatory response associated with starch intake.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

New nanobody antivenom offers broad protection against Indian cobras

Snakebite is a neglected tropical disease, causing hundreds of thousands of deaths and disabilities each year. India alone reports nearly 50,000 deaths every year, the most by snakebite in the world.

9 Sep 2026

Gut infection leaves long-lasting immune ‘memories’ at the brain’s borders in mice

In mice, intestinal infections reshaped dural CD4+ T-cell populations and seeded the brain’s outer meningeal border with antigen-specific memory cells that persisted for months and mounted rapid recall responses to bloodborne antigens. Oral priming was associated with reduced Salmonella spread to the brain and modest cross-protection in an engineered shared-antigen Candida model, although the researchers could not definitively prove that dural CD4+ T cells alone caused the protection.

9 Sep 2026

New AI method tracks immune responses without known antibody databases

A research team comprising Associate Professor FUNAKOSHI Yohei, Associate Professor YAKUSHIJIN Kimikazu, Professor MINAMI Hironobu, and Associate Professor OHJI Goh of Kobe University, together with graduate student MASUDA Genki, then-graduate student IIZUMI Shunsuke, Associate Professor OHUE Masahito, and colleagues at the Institute of Science Tokyo, has developed a new analysis method, LM-QASAS.

9 Sep 2026

Astrocyte changes may explain how stress affects mental health

A new study led by UCLA Health researchers has identified a specific type of brain cell and a tiny structure on its surface that changes when the body is under stress, which may help explain why stress can lead to anxiety and depression.

8 Sep 2026

UCLA researchers develop scalable TCR therapy for solid tumors

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It's similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside of a cancer cell.

8 Sep 2026

Two collagen receptors cooperate to enhance cranial bone regeneration

Bone repair depends on skeletal progenitor cells (SPCs) moving to injured areas and developing into bone-forming cells, but how these cells respond to their surroundings remains unclear.

8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

LSD deconstruction reveals promising new drug candidates

University of California, Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.

7 Sep 2026

GLP-1 treatment linked to 40% fewer asthma attacks

The diabetes and weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

7 Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

7 Sep 2026

GLP-1 drugs appear psychiatrically safe, but one finding still raises questions

A systematic review of 11 observational studies representing more than 4.9 million patients found that GLP-1 receptor agonists were generally associated with neutral or potentially protective psychiatric outcomes, although one obesity-focused cohort reported increased risks of depression, anxiety, and suicidal behavior. Direct evidence for antidepressant effects remains limited, with only one cross-sectional study using validated mood scales and no randomized trials in the final synthesis, meaning causality cannot be established

6 Sep 2026

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy, with cycle-matched dosing sustaining protection during repeated cisplatin exposure without measurably affecting tumor growth. Experiments in human-derived sensory neurons and ex vivo peripheral nerves linked the effect to 5-HT2A-dependent preservation of mitochondrial trafficking and local axonal energy supply, while a nonhallucinogenic 5-HT2A agonist reproduced protection against mechanical hypersensitivity.

6 Sep 2026

New study uncovers bacterial route to testosterone production

Many prostate cancers depend on androgen hormones, including testosterone, to grow. That is why treatments for advanced disease often try to reduce testosterone production or block its effects.

4 Sep 2026

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

Childhood obesity prescriptions for GLP-1 drugs surge in the U.S.

Although the number of US children under age 12 with obesity being prescribed the weight loss drugs Saxenda, Wegovy, and Zepbound remains low, the number is 310 times higher in June 2026 than it was in 2019, when the drugs were initially prescribed, a new study shows.

4 Sep 2026

What your gut microbes may have to do with how your brain ages

This review examines how diet-driven changes in the gut microbiota and microbial metabolites may influence cognitive aging through immune, metabolic, neural, endocrine, and barrier-related pathways. It highlights SCFAs, tryptophan-derived metabolites, and bile acids as key signaling mediators while emphasizing that much of the mechanistic evidence remains preclinical and human evidence is largely associative.

3 Sep 2026

The obesity-microbiome story is more complicated than ‘good’ and ‘bad’ bacteria

This review finds that obesity is linked to reciprocal interactions between diet, the gut microbiome, microbial metabolites, and host metabolic pathways that influence appetite, insulin sensitivity, inflammation, and energy balance across the lifespan. It highlights diet as a particularly tractable way to influence this system, while emphasizing that microbiome changes associated with GLP-1 therapies remain difficult to separate from weight loss and that functional multi-omics approaches may help enable more personalized interventions.

3 Sep 2026